Chronic inflammation of the digestive tract is referred to as inflammatory bowel disease (IBD), of which Crohn’s disease is a type. The small intestine (ileum) and the large intestine (colon) are the only organs affected. Sometimes fatal complications arise from the disease, which causes severe pain and impairment. Bowel obstruction, fistulas, ulcers, anal fissures, cancer of the colon, and other diseases and conditions may all contribute to these side effects. Some of the things that can lead to Crohn’s disease are mental or emotional strain, poor dietary choices, genetic predisposition, and immune system dysfunction. This illness can strike at any time in life. In most cases, however, it manifests itself at a young age.
The global crohn’s disease treatment market is expected to reach US$10.92 billion by 2022, growing at a CAGR of 4.2% from 2023 to 2030.
Get Exclusive Sample PDF Copy of the Report @ https://www.coherentmarketinsights.com/insight/request-sample/1237
The market for the treatment of inflammatory bowel diseases, such as Crohn’s, is expected to grow
The number of people diagnosed with Crohn’s disease and other forms of IBD is expected to rise, which will drive the market for treatments for Crohn’s disease. For example, an article published in May 2021 by the Journal BMC Gastroenterology describes the development of an illness-death model using existing data to forecast the prevalence of IBD in Asia, and Iran in particular, from 2017 to 2035. In 2035, the study predicted a 2.5-fold increase in prevalence from the 2020 level, with 69 thousand cases in Iran, a 2.3-fold increase from the 2020 level, with 220,000 cases in North Africa and the Middle East, a quadrupling of the prevalence from the 2020 level in India, a 1.5-fold increase from the 2020 level in the East Asia region, with 4.5 Mn cases, and a 1.6-fold elevation in prevalence from the 2020 level in high-income Asia-Pacific and Southeast
The introduction of more products and the research and development of more effective therapies to treat crohn’s disease symptoms are projected to drive the market forward over the next few years
The expansion of the Crohn’s disease treatment market is driven in large part by the discovery and development of novel and effective therapies for the treatment of Crohn’s disease symptoms. At the Crohn’s & Colitis Congress in January 2018, scientists from the University of Washington Medicine presented a study on a new antibiotic that showed a four-fold better response on the inflammation of the intestine among patients with Crohn’s disease than the current therapies on the market.
AbbVie Inc., Janssen Biotech, Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Pfizer Inc., Eli Lilly and Company, Novartis AG, Sanofi, Takeda Pharmaceutical Company Limited, Mylan N.V., Amgen Inc., and AstraZeneca are all major players in the global crohn’s disease treatment market.
Direct Buy This Premium Research Report: https://www.coherentmarketinsights.com/insight/buy-now/1237
Crohn’s Disease Treatment Market Report Coverage
|The market size value in 2023|
Global Crohn’s Disease Treatment Market– Impact of Coronavirus (COVID-19) Pandemic
Over a hundred countries have reported cases of COVID-19 since the outbreak in December 2019, and on January 30, 2020, the World Health Organization declared the situation a global public health emergency.
Because the COVID-19 pandemic caused acceleration in the progression of Crohn’s disease, it had a major effect on the market for Crohn’s disease treatments. Frontiers Media S.A., for example, reports in December 2021 that a questionnaire survey of patients with Inflammatory Bowel Disease (IBD) was conducted from June 16 to August 21, 2020, as part of the patients’ routine follow-up care at a hospital in Japan. 241 patients with UC and 210 patients with CD completed the survey; of these, 82 (34%) and 97 (46%), respectively, reported disease exacerbation within 2 months after the lockdown. The findings suggest that the disruptions to normal routine and increased levels of stress brought on by the pandemic and the lockdown measures contributed to an escalation of IBD symptoms, particularly among the young.
Global Crohn’s Disease Treatment Market: Key Developments
When it comes to treating adults with moderate to severe active Crohn’s disease, SKYRIZI (risankizumab-rzaa) is the first and only specific interleukin-23 (IL-23) inhibitor on the market. This was announced by AbbVie Inc., a biopharmaceutical company, on June 17, 2022. (CD).
Foralumab (TZLS-401) is a monoclonal antibody (mAb) that Tiziana Life Sciences, a biotechnology company, began testing in mild-to-moderate Crohn’s disease (CD) patients via oral enteric-coated capsules in March 2022.
Global Crohn’s Disease Treatment Market: Restraint
Low level of awareness about the alternatives to therapy among people, as well as the high cost of the drugs used to treat crohn’s disease, are the major factors that hinder the growth of the global crohn’s disease treatment market. Care costs for people with Crohn’s disease, for example, are estimated to be around US$ 30,000 in the year following their initial diagnosis, according to a 2019 study from the Crohn’s & Colitis Foundation.
Request for Enquiry or Customization @ https://www.coherentmarketinsights.com/insight/request-customization/1237
Table of Contents with Major Points:
- Key Findings
- Definitions and Assumptions
- Definition of Crohn’s Disease Treatment Market Market
- Market Dynamics
- Trends and Developments
- Key Emerging Trends
- Key Developments Mergers and Acquisition
- New Product Launches and Collaboration
- Partnership and Joint Venture
- Latest Technological Advancements
- Insights on Regulatory Scenario
- Porters Five Forces Analysis
Qualitative Insights Impact of COVID-19 on Global Crohn’s Disease Treatment Market Market
- Supply Chain Challenges
- Steps taken by Government/Companies to overcome this impact
- Potential opportunities due to COVID-19 outbreak
- Data Sources
Explore More Report:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
533 Airport Boulevard, Suite 400, Burlingame,
CA 94010, United States.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027